Results 231 to 240 of about 1,662,389 (298)
The Fallacy of Patient-Reported Outcome Measures: Why They Often Fail to Detect Clinically Important Differences. [PDF]
O'Hara NN +4 more
europepmc +1 more source
A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker +3 more
wiley +1 more source
It's not just a questionnaire: The ins and outs of using a patient-reported outcome measure. [PDF]
Williams LA.
europepmc +1 more source
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra +10 more
wiley +1 more source
Correction to: Estimation of the Harvey Bradshaw Index from the Patient Reported Outcome-2 in Crohn's Disease. [PDF]
europepmc +1 more source
Statewide integration of electronic patient-reported outcome measures into routine oncology care: a mixed-methods implementation study. [PDF]
Mazariego C +10 more
europepmc +1 more source
Identifying prognostic targets in metastatic prostate cancer beyond AR
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng +13 more
wiley +1 more source

